• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Sangamo Therapeutics, Inc. - Common Stock (NQ:SGMO)

    0.5980 +0.0260 (+4.55%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Sangamo Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
     
    Via Benzinga
    The Analyst Landscape: 6 Takes On Sangamo Therapeutics
     
    Via Benzinga
    J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
     
    Via Benzinga
    Earnings Scheduled For November 12, 2024
     
    Via Benzinga
    Sangamo Therapeutics's Earnings Outlook
     
    Via Benzinga
    Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    Zeta Global, Spirit Airlines And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
     
    Via Benzinga
    Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    4 Analysts Have This To Say About Sangamo Therapeutics
     
    Via Benzinga
    Why Is Sangamo Therapeutics (SGMO) Stock Up 52% Today?
    Sangamo Therapeutics stock is heading higher on Tuesday as SGMO investors react to a new $50 million license agreement. 
    Via InvestorPlace
    Peering Into Sangamo Therapeutics's Recent Short Interest
     
    Via Benzinga
    Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday
     
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
     
    Via Benzinga
    Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results
     
    Via Benzinga
    What's Going On With Sangamo Therapeutics Shares Tuesday?
    Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares are moving higher Tuesday after the company announced the FDA approved an accelerated pathway for ST-920, a potential gene therapy for the treatment of... 
    Via Benzinga
    Crude Oil Rises Sharply; 3M Posts Upbeat Earnings
     
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
     
    Via Benzinga
    Dow Falls Over 150 Points; General Motors Tops Q3 Views
     
    Via Benzinga
    Topics Stocks
    Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    FDA Approves Pfizer's Second Hemophilia Drug With Six Months
    Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly treatment reduces bleeding rates and offers convenience via an... 
    Via Benzinga
    Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    Why Sangamo Therapeutics Stock Is Soaring
    Sangamo Therapeutics shares are trading higher Tuesday after the company announced it has entered into a license agreement with Genentech to develop intravenously administered genomic medicines for... 
    Via Benzinga
    Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
    From Sangamo Therapeutics, Inc.
    Via Business Wire
    Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
     
    Via Benzinga
    Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?
    Little-known firm Sangamo Therapeutics is surging today, with SGMO stock up more than 40% on promising late-stage trial results. 
    Via InvestorPlace
    Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings
     
    Via Benzinga
    Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
     
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.